The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Avelumab (MSB0010718C), an anti-PD-L1 antibody, as a third-line treatment in patients with advanced gastric or gastroesophageal junction cancer: A phase Ib JAVELIN Solid Tumor trial.
 
Do-Youn Oh
No Relationships to Disclose
 
Albert C. Lockhart
Research Funding - Amgen (Inst); Bayer (Inst); CTI (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Lilly (Inst); Millennium (Inst); Novartis (Inst); Regeneron (Inst); Sanofi (Inst); Teva (Inst); Vertex (Inst); Zenyaku Kogyo (Inst)
 
Deborah Jean Lee Wong
No Relationships to Disclose
 
Matthew Hiram Taylor
No Relationships to Disclose
 
Marcis Bajars
No Relationships to Disclose
 
Anja von Heydebreck
No Relationships to Disclose
 
Markus H. Moehler
Honoraria - Amgen; Lilly/ImClone; Merck Serono; Roche/Genentech; Taiho Pharmaceutical
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Nordic Bioscience; Roche
 
Howard Safran
No Relationships to Disclose